Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML2588

Sigma-Aldrich

JNJ0966

≥98% (HPLC)

Synonym(s):

N-[2-[(2-Methoxyphenyl)amino]-4′-methyl[4,5′-bithiazol]-2′-yl]acetamide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C16H16N4O2S2
CAS Number:
315705-75-0
Molecular Weight:
360.45
MDL number:
MFCD02045222
UNSPSC Code:
12352200
NACRES:
NA.77
Pricing and availability is not currently available.

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

[s]1c(nc(c1c2nc([s]c2)Nc3c(cccc3)OC)C)NC(=O)C

InChI

1S/C16H16N4O2S2/c1-9-14(24-16(17-9)18-10(2)21)12-8-23-15(20-12)19-11-6-4-5-7-13(11)22-3/h4-8H,1-3H3,(H,19,20)(H,17,18,21)

InChI key

ZADCDCMLLGDCRM-UHFFFAOYSA-N

Biochem/physiol Actions

JNJ0966 is a potent and highly selective inhibitor of matrix metalloproteinase-9 (MMP-9) zymogen activation. It appears that JNJ0966 binds to a structural pocket in proximity to the MMP-9 zymogen cleavage site near Arg-106. JNJ0966 reduces disease severity in in a mouse experimental autoimmune encephalomyelitis (EAE) model. JNJ0966 does not inhibit activation of MMP-2 zymogen, and has no effect on MMP-1, MMP-2, MMP-3, MMP-9 or MMP-14 catalytic activity.
potent and highly selective inhibitor of matrix metalloproteinase-9 (MMP-9) zymogen activation

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000080671
0000080670
0000075951

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Robert H Scannevin et al.
The Journal of biological chemistry, 292(43), 17963-17974 (2017-09-02)
Aberrant activation of matrix metalloproteinases (MMPs) is a common feature of pathological cascades observed in diverse disorders, such as cancer, fibrosis, immune dysregulation, and neurodegenerative diseases. MMP-9, in particular, is highly dynamically regulated in several pathological processes. Development of MMP

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service